Condition
HR-positive, HER2-negative Advanced Breast Cancer clinical trials and research
As of November 12, 2026, Find a Trial lists 4 HR-positive, HER2-negative Advanced Breast Cancer clinical trials that are recruiting, at sites in 8 countries (most in China (2), Australia (1), Brazil (1)). By phase: Phase 2 (1), Phase 1/2 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 8Countries
Newest HR-positive, HER2-negative Advanced Breast Cancer clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Two doses of dalpiciclib plus letrozole for first-line HR-positive, HER2-negative advanced breast cancer | Phase 2 | Dalian, Liaoning and 1 other locations | Recruiting | Dec 16, 2025 |
| Evaluating TYK-00540 Tablets for Advanced Solid Tumors | Phase 1/2 | Shanghai, Shanghai Municipality and 1 other locations | Recruiting | Apr 29, 2025 |
| Predicting outcomes for advanced breast cancer patients treated with CDK4/6 inhibitors and endocrine therapy | — | Aviano and 23 other locations | Recruiting | Feb 3, 2025 |
| Evaluating BBO-10203 for advanced solid tumors | Phase 1 | Duarte, California and 43 other locations | Recruiting | Oct 3, 2024 |
All recruiting trials (4)
-
Two doses of dalpiciclib plus letrozole for first-line HR-positive, HER2-negative advanced breast cancer
This trial tests whether two different doses of dalpiciclib combined with letrozole work well as first treatment for people with HR-positive, HER2-negative advanced breast cancer.
-
Evaluating TYK-00540 Tablets for Advanced Solid Tumors
This study is testing a new medication called TYK-00540 to see if it can safely help people with advanced solid tumors, especially those with certain types of breast cancer, who haven't had success with other treatments.
-
Predicting outcomes for advanced breast cancer patients treated with CDK4/6 inhibitors and endocrine therapy
This study is trying to see how well different CDK4/6 inhibitors combined with hormone therapy work for people with advanced breast cancer and how safe they are.
-
Evaluating BBO-10203 for advanced solid tumors
This study is testing a new treatment called BBO-10203, alone and with another drug, to see if it can help people with advanced solid tumors, including certain types of breast cancer.
Related topics
Quick answers
How many HR-positive, HER2-negative Advanced Breast Cancer clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 8 countries. The most sites are in China (2 trials), Australia (1 trial), Brazil (1 trial), France (1 trial), South Korea (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 1, Phase 1/2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.